A Study of the Effects of Camoteskimab in Adults With Moderate to Severe Atopic Dermatitis

Inclusion Criteria:

1. Participants must be 18-75 years of age inclusive, at the time of signing theinformed consent.

2. Chronic AD for at least 1 year.

3. Participants with moderate to severe AD defined by:

4. Investigator global assessment (IGA) score of ≥ 3 (on a scale of 0 to 4, inwhich three is moderate and four is severe) at Baseline.

5. AD involvement of ≥ 10% body surface area (BSA) at Baseline.

6. EASI score of ≥ 12 at Baseline.

7. Pruritus numerical rating scale (NRS) ≥ 4 at Baseline.

8. Participants who are candidates for systemic therapy, defined as inadequate responseto treatment with topical medications, or for whom topical treatments are otherwisemedically inadvisable.

9. Contraceptive use should be consistent with local regulations regarding the methodsof contraception for those participating in clinical studies. Female participants:

• Sexually active females of childbearing potential must agree to use two formsof accepted methods of highly effective forms of contraception during thecourse of the study and for 3 months after their last dose of study drug.Effective birth control includes:

• IUD plus one barrier method.

• Stable doses of hormonal contraception for at least 3 months (e.g., oral,injectable, implant, transdermal) plus one barrier method.

• 2 barrier methods. Effective barrier methods are male or female condoms,diaphragms, and spermicides (creams or gels that contain a chemical to killsperm); or

• A vasectomized partner*. Male participants:

• Sexually active male participants and males and who are partners of females ofchildbearing potential agree to use two forms of contraception as above and tonot donate sperm or try to conceive during the treatment period and for atleast 3 months after the last dose of study drug.

6. Participant provides signed informed consent.

Exclusion Criteria:

1. Participant has history of use of more than two (2) prior systemic therapies for AD (e.g. biologics or JAKi) and who used any of these medications as follows:

2. Dupilumab, tralokinumab, lebrikizumab within 8 weeks prior to Baseline.

3. Systemic JAKi within 4 weeks prior to Baseline.

4. TCS, TCI, topical phosphodiesterase-4 (PDE4) inhibitors, and topical JAKiwithin 7 days prior to enrollment (at Baseline) or more than five half-liveswhichever is longer.

5. Participant has a current diagnosis of other active skin disease (e.g., psoriasis orlupus erythematosus) or skin infection (bacterial, fungal, or viral) that may affectthe evaluation of AD or would interfere with the study assessments.

6. Participant has a severe comorbidity that may require systemic steroids therapy orother interventions or requires active frequent monitoring (e.g., unstable chronicasthma).

7. Any clinically significant abnormalities in rhythm, conduction or morphology of theresting electrocardiogram (ECG) and any clinically significant abnormalities in the 12- lead ECG as considered by the perfusion index that may interfere with theinterpretation of QTc interval changes.

8. Participant has AD involving ocular symptoms, or blepharitis, conjunctivitis, orkeratitis diagnosed within the last 60 days prior to the screening visit, requiringchronic ocular corticosteroid treatment.

9. Participant has severe or uncontrolled seasonal or allergic rhinitis, asthma or anyother non-AD disease as judged by the Investigator. Participants with seasonal orallergic rhinitis, asthma or any other non-AD disease requiring use of intranasal orinhaled corticosteroid that is stable and well-controlled are not excluded.

10. Active human immunodeficiency virus (HIV): confirmed positive anti-HIV antibody (HIVAb) test; Active hepatitis B virus (HBV): confirmed hepatitis B surface antigen (HBsAg) positive (+) or hepatitis B core antibody (HBc Ab) positive (+); Activehepatitis C virus (HCV): Confirmed hepatitis C antibody positive (+); evidence ofactive or latent TB

11. Diagnosed with a malignancy within 5 years of enrollment (suspected malignancyshould be ruled out by blood or tissue biopsy, as applicable) with the exception of

• Completely resected basal call or squamous cell carcinoma of the skin.

• Carcinoma in situ of the cervix.

9. Has had previous exposure to anti-IL-18 therapy.

10. Treatment with any investigational agent, or any investigational device orprocedure, within 28 days (or 5 half- lives, whichever is greater) of screening.

11. Has any of the following laboratory findings

12. Glomerular filtration rate (GFR) < 30 mL/min/1.73 m2.

13. Hemoglobin ≤8 g/dL.

14. Neutrophils ≤1,500/μL.

15. Platelets ≤75,000/μL.